A recent phase 2 study from American researchers based at the Cleveland Clinic Foundation, found that Sutent treatment breaks are feasible and the clinical efficacy of the drug does not seem to be compromised. The study was published in Journal of Clinical Oncology last week.

The lead researcher, Dr Moshe Ornstein said “Based on our clinical practice, we were certainly expecting to see patients tolerate some breaks from sunitinib therapy. What was more interesting, however, was the range of breaks patients were able to experience without having disease progression”.

Read the Cure article here and the HemOnc Today article here